Abstract Background The present research was aimed to develop a self-microemulsifying drug delivery system (SMEDDS) pellet to increase the dissolution rate and in vivo hypoglycemic effect of gliclazide. Gliclazide belongs to BCS class 2 and it exhibits dissolution rate-limited absorption. Thus. dissolution enhancement of gliclazide from its dosage form is a prime requirement to achiev... https://ashleyshomestores.shop/product-category/27-single-true-convection-wall-oven/